Surface plasmon polariton probe and self-adaptive trace controlled-release adventitia drug delivery system

Through surface plasmon probes and adaptive microcontrolled release vascular epimembrane drug delivery system, the problems of inaccurate drug release and insufficient detection accuracy of metasurface technology in microneedle array technology are solved, and personalized drug release and high Bioavailability reduces side effects.

CN118925050APending Publication Date: 2024-11-12BEIJING HOSPITAL
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411143187.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing microneedle array technology is difficult to achieve precise controlled release of drugs, and the detection accuracy and stability of metasurface technology are insufficient, resulting in low bioavailability of drugs and greater side effects.

Method used

The surface plasmon probe and adaptive microcontrolled release vascular epimembrane drug delivery system are used to achieve real-time monitoring and dynamic feedback through a combination of high-numerical aperture objective lens, metasurface and hollow microneedle arrays, combined with optical technology, and accurately regulate drug release.

Benefits of technology

It realizes the precise controlled release of drugs, improves bioavailability, reduces the side effects of drugs, and improves the precise detection accuracy and stability of characteristic parameters of the outer membrane of vascular tissue fluid.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118925050A_ABST
    Figure CN118925050A_ABST
Patent Text Reader

Abstract

The invention discloses a surface plasmon polariton probe and a self-adaptive trace controlled release vascular adventitia drug delivery system. The polariton probe comprises a high numerical aperture objective lens, a super surface, a hollow microneedle array and a microneedle delivery module, the metasurface and the hollow microneedle array are combined into a composite microneedle surface; the microneedle delivery module is composed of an injection assembly, a medicine storage assembly and a flexible substrate. The device is simple in structure, integrates multiple functions of real-time monitoring of physical sign parameters, dynamic feedback and self-adaptive regulation and control of the drug controlled release amount, and realizes accurate control of the drug release amount of the microneedle array and accurate detection of the characteristic parameters of the vascular adventitia tissue fluid, so that personalized release of the drug is realized, and the service life of the drug is prolonged. The bioavailability of the medicine is improved, and the side effects of the medicine are reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the cross-technical field of near-field optical manipulation technology, microneedle array technology and drug controlled release technology, and specifically relates to a surface plasmon probe and an adaptive micro-controlled release vascular adventitial drug delivery system. Background Art

[0002] Microneedle is an emerging physical penetration-promoting technology that achieves precise drug delivery by piercing a tiny needle array into the skin. The advantage of this technology is that it can avoid drug degradation in the gastrointestinal tract, improve drug bioavailability, and reduce drug side effects. However, the key issue of microneedle array technology is how to accurately control the amount of drug released and how to accurately detect the characteristic parameters of the adventitial tissue fluid in order to better understand the physiological state of the organism and provide a basis for the precise controlled release of drugs. Metasurface technology is an emerging optical technology that modulates the incident light wavefront to generate a high-order excitation light source and excite the metal surface to generate multipolar surface plasmon probes. The advantage of this technology is that it can achieve precise detection of the characteristic parameters of the adventitial tissue fluid, thereby better characterizing the physiological state of the organism. Drug controlled release technology is an emerging drug delivery technology that can achieve precise controlled release of drugs by designing different drug carriers and controlled release mechanisms. The advantage of this technology is that it can improve the bioavailability of drugs and reduce drug side effects.

[0003] The existing solutions are mainly to achieve precise controlled release of drugs by designing different microneedle structures and drug carriers, and adopting different controlled release mechanisms. At the same time, various detection and analysis equipment, such as biosensors, imaging equipment, etc., are used to achieve accurate detection of characteristic parameters of vascular adventitial tissue fluid. Although the existing technology has solved the problems of controlled drug release and detection of characteristic parameters of vascular adventitial tissue fluid to a certain extent, there are still some problems and shortcomings. First, the existing microneedle array technology often cannot achieve precise controlled release of drugs, resulting in low absorption and utilization efficiency of drugs. Secondly, although the existing supersurface technology can achieve precise detection of characteristic parameters of vascular adventitial tissue fluid, its detection accuracy and stability still need to be improved. Finally, the existing drug controlled release technology often cannot achieve adaptive micro-controlled release of drugs, resulting in low bioavailability of drugs and large side effects. Summary of the invention

[0004] The present invention aims to address the deficiencies of the prior art and proposes a surface plasmon probe and an adaptive micro-controlled release adventitial drug delivery system, which integrates real-time monitoring, dynamic feedback, and precise regulation functions to achieve adaptive controlled release of drugs, thereby improving the bioavailability of drugs and reducing the side effects of drugs.

[0005] To achieve the above object, the present invention provides the following solutions:

[0006] A surface plasmon probe, comprising: a high numerical aperture objective lens, a metasurface, a hollow microneedle array and a microneedle delivery module;

[0007] The super surface and the hollow microneedle array are combined into a composite microneedle surface;

[0008] The microneedle delivery module consists of an injection component, a drug storage component and a flexible substrate.

[0009] Preferably, the material of the super surface is a gold-plated metal plane or a silver-plated metal plane;

[0010] The refractive index of the metasurface is 0.54386+2.2309i or 0.0511+1.67i.

[0011] Preferably, the metasurface is modulated using an Optical Pen, and the steps of modulating the metasurface include: high-order vector vortex beam excitation, mode extraction phase and modulation phase;

[0012] The method for exciting the high-order vector vortex beam comprises:

[0013]

[0014]

[0015] Where VVBs represents high-order vector vortex beams, E VVBs represents the annular surface plasmon electric field generated by the vector vortex beam exciting the metasurface, T m represents the transmittance function of the mask placed in front of the high numerical aperture objective, T p represents the coding filter function, represents the azimuth of the focusing system, e r represents the radial electric field component, are the radial and angular electric field components, respectively, m represents the order of the incident light VVBs, β0 is the excitation angle of the surface plasmon electric field, α is the maximum convergence angle, θ represents the convergence angle of the focusing system, tp represents the p-component of VVBs, t s represents the s-component of VVBs, t prv represents the Fresnel transmittance coefficient of the p-component of the high-order vector vortex beam at the r / v interface, t srv represents the Fresnel transmittance coefficient of the s-component of the high-order vector vortex beam at the r / v interface, r pij represents the Fresnel transmittance coefficient at the r / v interface, r srv represents the Fresnel refractive index coefficient at the r / v interface, d represents the thickness of the metal layer, k2z represents the wave vector in z direction;

[0016] The method for extracting the phase of the mode comprises:

[0017]

[0018] Among them, E v represents the annular surface plasmon electric field, M represents the electric field order, represents a high-order vector vortex beam with polarization direction β, represents the phase modulation of the Tc order, i represents the imaginary part; when Tc = 0 and M = n, an integer-order SPPs probe is obtained, and when Tc = l + 0.5 and M = n + 0.5 is a fraction, a fractional-order SPPs probe is obtained;

[0019] The method for modulating phase includes:

[0020]

[0021] T p =exp(iΩ p )

[0022] Among them, ψ pen represents the modulation phase function of the Optical Pen, Phase{} represents the phase angle, N represents the number of SPPs probes, and PF represents the parameter x j ,y j 、z j 、s j and δ j The phase function, x j ,y j and z j represents the position coordinates of the jth SPPs probe, s j represents the amplitude of the probe, δ j represents the phase of the probe, Ω p Represents the entire incident beam wavefront modulation phase.

[0023] The present invention also provides an adaptive micro-controlled release adventitial drug delivery system using an excimer probe, the drug delivery system comprising any of the excimer probes described above, and further comprising: a light source module, a beam splitter prism, a modulation unit, a high-order vortex paddle, a reflector, a dichroic mirror, a microneedle control device, and a signal acquisition and analysis module;

[0024] The light source module, the beam splitter prism, the high-order vortex paddle and the reflector are arranged on a first optical path;

[0025] The beam splitter prism also forms a second optical path with the modulation unit;

[0026] The reflector also forms a third optical path with the dichroic mirror and the excimer probe;

[0027] The dichroic mirror also forms a fourth optical path with the signal acquisition and analysis module;

[0028] The microneedle regulating device is electrically connected to the excimer probe and the signal acquisition and analysis module respectively.

[0029] Preferably, the workflow of the drug delivery system includes:

[0030] The light beam generated by the light source module is split by the beam splitter prism, and one beam of light is incident on the modulation unit through the second optical path, returns to the beam splitter prism after wavefront coding modulation, and is superimposed with the other beam of light and incident on the high-order vortex paddle to generate a high-order excitation light source;

[0031] The high-order excitation light source changes direction through the reflector, passes through the dichroic mirror and is incident on the high numerical aperture objective lens to excite the hollow microneedle array and the SPPs probes on the metasurface;

[0032] The hollow microneedle array and the SPPs probe act together on the skin surface through the microneedle delivery module: the SPPs probe acts on the characteristic substances of the adventitial tissue fluid of the blood vessels to detect characteristic parameters; the hollow microneedle array completes subcutaneous high permeability and high penetration injection administration;

[0033] The spectrum generated by the SPPs probe containing the array-loaded vital sign information of the characteristic parameters is screened by the dichroic mirror, incident on the signal acquisition and analysis module for analysis, and the analysis result is obtained, and the analysis result is fed back to the microneedle control device;

[0034] The microneedle control device determines the drug controlled release dosage of the excimer probe based on the analysis result, and controls the drug controlled release process of the excimer probe.

[0035] Preferably, the signal acquisition and analysis module comprises: an optical signal acquisition module and a PC terminal;

[0036] The optical signal acquisition module is used to receive the spectrum of the array loaded vital sign information and convert the spectrum into an electrical signal;

[0037] The PC end is used to analyze the electrical signal to obtain the analysis result.

[0038] Compared with the prior art, the present invention has the following beneficial effects:

[0039] The present invention has a simple structure and integrates the functions of real-time monitoring of vital sign parameters, dynamic feedback and adaptive regulation of drug controlled release, thereby achieving precise control of the drug release amount of the microneedle array and precise detection of characteristic parameters of the vascular adventitial tissue fluid, thereby achieving personalized release of the drug, improving the bioavailability of the drug and reducing the side effects of the drug. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] In order to more clearly illustrate the technical solution of the present invention, the following briefly introduces the drawings required for use in the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative labor.

[0041] Figure 1 is a schematic structural diagram of an excimer probe according to an embodiment of the present invention;

[0042] Figure 2 Schematic diagram of the structure of the drug delivery system according to an embodiment of the present invention.

[0043] Description of reference numerals:

[0044] 1. Light source module; 2. Beam splitter; 3. Modulation unit; 4. High-order vortex paddle; 5. Reflector; 6. Dichroic mirror; 7. Exciton probe; 8. Microneedle control device; 9. Signal acquisition and analysis module; 7-1. High numerical aperture objective lens; 7-2. Metasurface; 7-3. Hollow microneedle array; 7-4. Microneedle delivery module; 9-1. Optical signal acquisition module; 9-2. PC terminal. DETAILED DESCRIPTION

[0045] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0046] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.

[0047] Embodiment 1

[0048] In this embodiment, if Figure 1 As shown, a surface plasmon probe includes: a high numerical aperture objective lens 7-1, a metasurface 7-2, a hollow microneedle array 7-3 and a microneedle delivery module 7-4.

[0049] The super surface 7-2 and the hollow microneedle array 7-3 are combined into a composite microneedle surface. The material of the super surface 7-2 is a gold-plated metal plane or a silver-plated metal plane; the refractive index of the super surface 7-2 is 0.54386+2.2309i or 0.0511+1.67i. The microneedle delivery module 7-4 is composed of an injection component, a drug storage component and a flexible substrate.

[0050] In this embodiment, the hollow microneedle array 7-3 in the excimer probe 7 is equipped with a microneedle delivery module 7-4 including an injection component, a drug storage component and a flexible substrate. The hollow microneedle array 7-3 is processed by 3D printing technology, and the material is selected from polymers, silicon, metals or biodegradable materials, which are biocompatible, wherein the microneedles correspond to the through holes of the injection component one by one, and the drug storage component is connected to the injection component; the hollow microneedle array 7-3 extends from a base surface of the flexible substrate respectively. More specifically, the shape of the hollow microneedle array 7-3 is one of a cone and a pentagonal or hexagonal pyramid. The cross-section of the microneedle gradually decreases as it moves away from the flexible substrate, forming a pointed tip at the end point and being hollow inside. The length of the hollow microneedle array 7-3 is 4 to 7 mm in typical skin areas, about 5 to 8 mm in areas such as the abdomen or thighs, and 8 to 10 mm or even longer in areas with thicker deep subcutaneous tissue. It can penetrate the skin tissue to reach the vascular adventitia but cannot penetrate the vascular wall. The height of the hollow microneedle is one of 500 μm, 600 μm, 800 μm, and 900 μm.

[0051] In this embodiment, the optical pen is used to modulate the metasurface 7-2 to obtain an SPPs probe array. The steps of modulating the metasurface 7-2 include: high-order vector vortex beam excitation, mode extraction phase and modulation phase.

[0052] Methods for high-order vector vortex beam excitation include:

[0053]

[0054] Where VVBs represents high-order vector vortex beams, E VVBs It indicates that the high-order vector vortex beam excites the metasurface to generate a ring-shaped surface plasmon polaritons (SPPs), T m represents the transmittance function of the mask placed in front of the high numerical aperture objective, T p represents the coding filter function, T p The metasurface is a sandwich structure consisting of three layers of glass, metal plane and air. The incident light reaching the metasurface needs to satisfy the Fresnel law. represents the azimuth of the focusing system, e r represents the radial electric field component, are the radial and angular electric field components, e r and are all vector units of the excitation electric field, m represents the order of the incident light VVBs, β0 is the excitation angle of the surface plasmon electric field, also known as the resonance angle, which is about 43°, α is the maximum convergence angle, and θ represents the convergence angle of the focusing system. In addition, according to the Fresnel law, the incident light VVBs contains two components, p- and s-, namely t p and t s , t p represents the p-component of VVBs, t s represents the s-component of VVBs, and has different transmittances in the annular SPPs, which requires coding filter Tp modulation. tprv represents the Fresnel transmittance coefficient of the p-component of the high-order vector vortex beam at the r / v interface, and t srv represents the Fresnel transmittance coefficient of the s-component of the high-order vector vortex beam at the r / v interface, r pij represents the Fresnel transmittance coefficient at the r / v interface, r srv represents the Fresnel refractive index coefficient at the r / v interface, r, v = 1, 2, 3, corresponding to the three-layer structure of glass, metal plane and air of the metasurface, d represents the thickness of the metal layer, k 2z represents the wave vector in the z direction.

[0055] Methods for extracting the phase of a pattern include:

[0056]

[0057] Among them, E v represents the SPPs electric field, M represents the electric field order, represents a high-order vector vortex beam with polarization direction β, represents the phase modulation of the Tc order, i represents the imaginary part; the incident high-order vector vortex beam is modulated by the mode extraction phase to obtain several SPPs probes: when Tc=0 and M=n, an integer-order SPPs probe is obtained, and the corresponding phase is When Tc = l + 0.5 and M = n + 0.5 is a fraction, a fractional-order SPPs probe is obtained, and the corresponding phase is Where l and n are both integers, ranging from (-∞,∞).

[0058] Methods for modulating the phase include:

[0059]

[0060] T p =exp(iΩ p )

[0061] Among them, ψ penrepresents the modulation phase function of "Optical Pen", Phase{} represents the phase angle, N represents the number of SPPs probes, and PF represents the parameter x j ,y j 、z j 、s j and δ j The phase function, x j ,y j 、z j Represents the position coordinates of the jth SPPs probe, using x j ,y j and z j Dynamically control the number and position of optical tweezers, s j represents the amplitude of the probe, δj represents the phase of the probe, and s j and δ j Modulate the intensity and phase of the SPPs probe, Ω p It represents the entire incident beam wavefront modulation phase, including the mode extraction phase and the Optical Pen modulation phase. Finally, the "Optical Pen" modulation phase and the mode extraction phase are superimposed to form the coding filter function T p , completing the metasurface 7-2 modulation.

[0062] The modulation process is achieved when the focusing lens is a high numerical aperture objective lens 7-1 and interacts with the metasurface 7-2 to meet the resonance condition. In this embodiment, the high numerical aperture objective lens 7-1 is a numerical aperture NA = 1.49 oil immersion objective lens or a numerical aperture NA = 0.95 oil immersion objective lens; the metasurface 7-2 is a gold-plated metal plane or a silver-plated metal plane, and the refractive index is 0.54386+2.2309i or 0.0511+1.67i; the resonance condition is the incident angle of the incident light when a clear resonance ring appears on the metal plane, also called the resonance angle, which is about 43°.

[0063] Embodiment 2

[0064] In this embodiment, if Figure 2 As shown, an adaptive micro-controlled release vascular adventitial drug delivery system using an excimer probe includes: a light source module 1, a beam splitter prism 2, a modulation unit 3, a high-order vortex paddle 4, a reflector 5, a dichroic mirror 6, an excimer probe 7, a microneedle control device 8 and a signal acquisition and analysis module 9.

[0065] The light source module 1, the beam splitter prism 2, the high-order vortex paddle 4 and the reflector 5 are arranged on the first optical path; the beam splitter prism 2 also forms a second optical path with the modulation unit 3; the reflector 5 also forms a third optical path with the dichroic mirror 6 and the excimer probe 7; the dichroic mirror 6 also forms a fourth optical path with the signal acquisition and analysis module 9; the microneedle control device 8 is electrically connected to the excimer probe 7 and the signal acquisition and analysis module 9 respectively.

[0066] In this embodiment, the light source module 1 is one of 780nm, 800nm, and 1064nm lasers; the beam splitter 2 is a polarization beam splitter prism 2 or a beam splitter prism 2 suitable for 780nm, 800nm, and 1064nm wavelengths; the modulation unit 3 is a reflective phase-type spatial light modulator and a phase delay plate; the high-order vortex wave plate is a 30th-order or 60th-order vortex wave plate; the reflector 5 is a dielectric film reflector 5 suitable for 780nm, 800nm, and 1064nm wavelengths; the dichroic mirror 6 is a H-K9L dichroic beam splitter plate and an ultraviolet fused quartz dichroic beam splitter plate suitable for 780nm, 800nm, and 1064nm wavelengths; the microneedle control device 8 is a device for controlling the drug delivery speed, drug delivery time, and drug delivery dosage, and is one of a microfluidic pump, a microprocessor control system, and a micromotor drive module; the optical signal acquisition and analysis module 9 is a charge coupled device, a photodiode, and a complementary metal oxide semiconductor.

[0067] The workflow of the drug delivery system includes:

[0068] The light beam generated by the light source module 1 is split by the beam splitter prism 2, and one beam of light is incident on the modulation unit 3 through the second optical path, returns to the beam splitter prism 2 after wavefront coding modulation, and is superimposed with the other beam of light and incident on the high-order vortex paddle 4 to generate a high-order excitation light source; the high-order excitation light source changes direction through the reflector 5, passes through the dichroic mirror 6 and is incident on the high numerical aperture objective lens 7-1, exciting the hollow microneedle array 7-3 and the SPPs probe of the metasurface 7-2; the hollow microneedle array 7-3 and the SPPs probe act together on the skin surface through the microneedle delivery module 7-4: the SPPs probe acts on the characteristic substances of the vascular adventitia tissue fluid to detect the characteristic parameters; the hollow microneedle array 7-3 completes the subcutaneous high permeability and high-penetration injection; the spectrum of the array-loaded vital sign information containing characteristic parameters generated by the SPPs probe is screened by a dichroic mirror 6, incident on the signal acquisition and analysis module 9 for analysis, and the analysis result is obtained, and the analysis result is fed back to the microneedle control device 8. Specifically, the signal acquisition and analysis module 9 includes: an optical signal acquisition module 9-1 and a PC terminal 9-2; the optical signal acquisition module 9-1 is used to receive the spectrum of the array-loaded vital sign information and convert the spectrum into an electrical signal; the PC terminal 9-2 is used to analyze the electrical signal to obtain the analysis result; the microneedle control device 8 determines the drug controlled release dose of the excimer probe 7 based on the analysis result, and controls the drug controlled release process of the excimer probe 7.

[0069] The embodiments described above are only descriptions of the preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A surface plasmon probe, characterized in that: include: High numerical aperture objective lenses, metasurfaces, hollow microneedle arrays, and microneedle delivery modules; The super surface and the hollow microneedle array are combined into a composite microneedle surface; The microneedle delivery module consists of an injection component, a drug storage component and a flexible substrate.

2. A surface plasmon probe according to claim 1, characterized in that: The material of the super surface is a gold-plated metal plane or a silver-plated metal plane; The refractive index of the metasurface is 0.54386+2.2309i or 0.0511+1.67i.

3. A surface plasmon probe according to claim 1, characterized in that: The metasurface is modulated by using an optical pen, wherein the steps of modulating the metasurface include: high-order vector vortex beam excitation, mode extraction phase and modulation phase; The method for exciting the high-order vector vortex beam comprises: Where VVBs represents high-order vector vortex beams, E VVBs represents the annular surface plasmon electric field generated by the vector vortex beam exciting the metasurface, T m represents the transmittance function of the mask placed in front of the high numerical aperture objective, T p represents the coding filter function, represents the azimuth of the focusing system, e r represents the radial electric field component, are the radial and angular electric field components, respectively, m represents the order of the incident light VVBs, β0 is the excitation angle of the surface plasmon electric field, α is the maximum convergence angle, θ represents the convergence angle of the focusing system, and t p represents the p-component of VVBs, ts represents the s-component of VVBs, tprv represents the Fresnel transmittance coefficient of the p-component of the high-order vector vortex beam at the r / v interface, and tsr v represents the Fresnel transmittance coefficient of the s-component of the high-order vector vortex beam at the r / v interface, rpi j represents the Fresnel transmittance coefficient at the r / v interface, rsrv represents the Fresnel refractive index coefficient at the r / v interface, d represents the thickness of the metal layer, k 2z represents the wave vector in z direction; The method for extracting the phase of the mode comprises: Where Ev represents the annular surface plasmon electric field, M represents the electric field order, represents a high-order vector vortex beam with polarization direction β, represents the phase modulation of the Tc order, i represents the imaginary part; when Tc = 0 and M = n, an integer-order SPPs probe is obtained, and when Tc = l + 0.5 and M = n + 0.5 is a fraction, a fractional-order SPPs probe is obtained; The method for modulating phase includes: T p p=exp(122) Where ψpen represents the modulation phase function of the Optical Pen, Phase{} represents the phase angle, N represents the number of SPPs probes, and PF represents the parameter x j ,y j 、z j 、s j and the phase function of δj, x j ,y j and z j represents the position coordinates of the jth SPPs probe, s j represents the amplitude of the probe, δj represents the phase of the probe, and Ωp represents the modulation phase of the entire incident beam wavefront.

4. An adaptive micro-controlled release adventitial drug delivery system using an excimer probe, the drug delivery system comprising the excimer probe according to any one of claims 1 to 3, characterized in that: Also includes: Light source module, beam splitter, modulation unit, high-order vortex paddle, reflector, dichroic mirror, microneedle control device and signal acquisition and analysis module; The light source module, the beam splitter prism, the high-order vortex paddle and the reflector are arranged on a first optical path; The beam splitter prism also forms a second optical path with the modulation unit; The reflector also forms a third optical path with the dichroic mirror and the excimer probe; The dichroic mirror also forms a fourth optical path with the signal acquisition and analysis module; The microneedle regulating device is electrically connected to the excimer probe and the signal acquisition and analysis module respectively.

5. The adaptive micro-controlled release adventitial drug delivery system using excimer probes according to claim 4, characterized in that: The workflow of the drug delivery system includes: The light beam generated by the light source module is split by the beam splitter prism, and one beam of light is incident on the modulation unit through the second optical path, returns to the beam splitter prism after wavefront coding modulation, and is superimposed with the other beam of light and incident on the high-order vortex paddle to generate a high-order excitation light source; The high-order excitation light source changes direction through the reflector, passes through the dichroic mirror and is incident on the high numerical aperture objective lens to excite the hollow microneedle array and the SPPs probes on the metasurface; The hollow microneedle array and the SPPs probe act together on the skin surface through the microneedle delivery module: the SPPs probe acts on the characteristic substances of the adventitial tissue fluid of the blood vessels to detect characteristic parameters; the hollow microneedle array completes subcutaneous high permeability and high penetration injection administration; The spectrum generated by the SPPs probe containing the array-loaded vital sign information of the characteristic parameters is screened by the dichroic mirror, incident on the signal acquisition and analysis module for analysis, and the analysis result is obtained, and the analysis result is fed back to the microneedle control device; The microneedle control device determines the drug controlled release dosage of the excimer probe based on the analysis result, and controls the drug controlled release process of the excimer probe.

6. The adaptive micro-controlled release adventitial drug delivery system using excimer probes according to claim 5, characterized in that: The signal acquisition and analysis module includes: an optical signal acquisition module and a PC terminal; The optical signal acquisition module is used to receive the spectrum of the array loaded vital sign information and convert the spectrum into an electrical signal; The PC end is used to analyze the electrical signal to obtain the analysis result.

Citation Information

Cited By

  • Construction method and application of animal model for cardiomyopathy induced by circulating system

    CN120391393A